ALLO News and Press, Allogene Therapeutics Inc. From 11/04/21

Allogene Therapeutics, Inc. (ALLO) Q3 2021 Earnings Conference Call November 04, 2021 5:00 PM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President of Research ...

Allogene Therapeutics (NASDAQ:ALLO): Q3 GAAP EPS of -$0.57 misses by $0.01. The Company had $861.7 million in cash, cash equivalents, and investments as of September 30, 2021. Press Release Allogene continues to expect full year GAAP Operating Expenses to be between $300 and $330 million incl...

New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials to be Presented at the 63rd Annual Meeting of the American Society of Hematology ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patie...

ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell Lymphoma ALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in...

Poseida has built a non-viral genome engineering platform to develop safer cell therapies in oncology. This platform could enable outpatient use and expand the number of patients who can receive a cell therapy as well as bringing in substantial partnerships. Poseida's lead drug ca...

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) ther...

Allogene was hit with a clinical hold for the entirety of their allogeneic CAR T cell pipeline several days ago. The cause of the clinical hold was a chromosomal abnormality found in the CAR T cells within the patient. The possible ramifications of this clinical hold could affect ...

After the Food and Drug Administration paused Allogene Therapeutics ' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. It has rebounded 31% this week through Thursday, according to data from S&P Global Market Intelligence . That still leaves it down 30% s...

Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend for the next several years. The breast cancer drugs mark...

Gainers: Hyzon Motors HYZN +5%. Avadel Pharmaceuticals (NASDAQ:AVDL) +4%. Allogene Therapeutics (NASDAQ:ALLO) +4%. Latch (NASDAQ:LTCH) +2%. Old National Bancorp (NASDAQ:ONB) +2%. Losers: Xiaobai Maimai (NASDAQ:HX) -4%. Clarus Therapeutics Holdings (NASDAQ:CRXT) -4%. Relay Thera...